核心观点和黄医药公布24 年业绩,肿瘤产品收入增长65%,超出此前公司给出的全年30-50%增长指引;24 年呋喹替尼海外商业化亮眼,首个完整年销售额突破2.9 亿美元。公司2025 年肿瘤业务收入指引为3.5-4.5 亿美元。2025 年重点关注:(1)赛沃替尼SAVANNAH 以及SACHI 临床数据读出及新适应症国内获批进展;(2)呋喹替尼海外商业化表现;(3)索乐匹尼布国内获批上市以及海外...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.